Overview

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Reata Pharmaceuticals, Inc.
Collaborator:
AbbVie